All In Biotech

Drug Trial Radar · NCT07695285

Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 992 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

992

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Sep 1, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, randomized controlled trial aims to investigate the perioperative use of lemborexant, an orexin receptor antagonist, for reducing postoperative delirium (POD) in elderly patients undergoing general anesthesia.

Conditions

  • Postoperative Delirium

Interventions

  • Lemborexant PillDrug

    The intervention group will take Lemborexant tablets four times during the perioperative period

  • Placebo tabletDrug

    The control group will take placebo tablets with the same appearance, smell and properties as the intervention group four times during the perioperative period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of PODTime frame: The 1st to 5th day after the operation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.